<DOC>
	<DOCNO>NCT01554982</DOCNO>
	<brief_summary>A long-term safety study ferric citrate ( KRX-0502 ) renal failure patient complete study KRX-0502-304 . Only patient participate KRX-0502-304 trial may participate trial .</brief_summary>
	<brief_title>A Long-Term Safety Extension Trial Ferric Citrate Patients With End-Stage Renal Disease ( ESRD ) Dialysis</brief_title>
	<detailed_description>This study open-label , 48-week safety extension Study KRX-0502-304 ( Study 304 ) , evaluate safety long-term use KRX-0502 subject ESRD 2 year cumulative exposure . Subjects complete Safety Assessment Period ( SAP ) , eligible , Efficacy Assessment Period ( EAP ) Study 304 , independent assign treatment arm SAP EAP Study 304 , eligible participation long-term safety extension study . No new subject permit enter study .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Males nonpregnant , nonbreastfeeding female participate Safety Assessment Period ( SAP ) , eligible , Efficacy Assessment Period ( EAP ) Study KRX0502304 2 . Willing able give inform consent 1 . Subjects KRX0502 ( ferric citrate ) KRX0502304 treatment failure first period 2 . Any subject Study KRX0502304 SAP early terminate trial 3 . Any subject participate Study KRX0502304 decline EAP 4 . Actively symptomatic gastrointestinal bleeding inflammatory bowel disease 5 . History malignancy last five year 6 . Previous intolerance KRX0502 ( ferric citrate ) 7 . Intolerance oral ironcontaining product 8 . Absolute requirement oral iron therapy 9 . Absolute requirement Vitamin C ( multivitamin [ Nephrocaps , Renaphro , etc . ] allow ) 10 . Absolute requirement calcium , magnesium , aluminumcontaining drug meal 11 . Inability tolerate oral drug intake 12 . Any medical condition render subject unable unlikely complete trial would interfere optimal participation trial produce significant risk subject 13 . Inability cooperate study personnel history noncompliance 14 . Unsuitable trial per Principal Investigator 's ( PI ) clinical judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Participation Limited</keyword>
	<keyword>Long Term</keyword>
	<keyword>Safety Extension</keyword>
</DOC>